220 related articles for article (PubMed ID: 12653924)
1. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
3. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
5. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
6. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
8. Role of radiation therapy in mycosis fungoides refractory to systemic therapy.
de Sanctis V; Persechino S; Fanelli A; Valeriani M; Bracci S; D'Arienzo M; Monarca B; Caperchi C; Raffa S; Enrici RM
Eur J Dermatol; 2011; 21(2):213-7. PubMed ID: 21489904
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
10. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
11. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
12. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
13. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
[TBL] [Abstract][Full Text] [Related]
14. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
Apisarnthanarax N; Talpur R; Ward S; Ni X; Kim HW; Duvic M
J Am Acad Dermatol; 2004 Apr; 50(4):600-7. PubMed ID: 15034511
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
16. Follicular mycosis fungoides: variability of a rare entity.
Roeschm A; Schleyer V; Landthaler M; Vogt T
Skinmed; 2005; 4(1):12-7. PubMed ID: 15654159
[TBL] [Abstract][Full Text] [Related]
17. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH; Martinez G; Varghese A; Hoppe RT
Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
19. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J; Cowper S; Moss J; Girardi M
J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
[TBL] [Abstract][Full Text] [Related]
20. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
